Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis
Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.
Read More
Myelofibrosis Treatment Approaches after Disease Progression
A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.
Read More
Clinical Scenario: A 67-Year-Old with Myelofibrosis
Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.
Read More
Management of Accelerated Phase Myeloproliferative Neoplasms
Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.
Read More
Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022
Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.
Read More
Efficacy and Safety of JAK Inhibitors for Myelofibrosis
Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.
Read More
Risk Stratification for Myelofibrosis
The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.
Read More
Myeloproliferative Neoplasms: Myelofibrosis
Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.
Read More
Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms
A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.
Read More
PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera
Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.
Read More
Myeloproliferative Neoplasms: Polycythemia Vera
Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.
Read More
Managing Patients with Essential Thrombocythemia
Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.
Read More